Renal Involvement in Children with Vasculitis

  • Seza Ozen
  • Diclehan Orhan
Living reference work entry


Vasculitis is the inflammation in a blood vessel wall. This inflammation leads to narrowing or aneurysm of the vessel resulting in protean manifestations in the tissue that it nourishes. The kidney is one of the target organs frequently affected in vasculitis.


Kawasaki Disease Familial Mediterranean Fever Renal Involvement Takayasu Arteritis Crescentic Glomerulonephritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34.PubMedCrossRefGoogle Scholar
  3. 3.
    Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Lightfoot Jr RW, Michel BA, Bloch DA, Hunder GG, Zvaifler NJ, McShane DJ, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33(8):1088–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–41.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798–806.PubMedCrossRefGoogle Scholar
  7. 7.
    Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi. 1967;16(3):178–222.PubMedGoogle Scholar
  8. 8.
    Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Sundel RP, Petty RE. Kawasaki disease. In: Cassidy J, Petty R, Laxer R, Lindsley C, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier; 2005. p. 521–38.CrossRefGoogle Scholar
  10. 10.
    Brogan PA, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child. 2002;86(4):286–90.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Nardi PM, Haller JO, Friedman AP, Slovis TL, Schaffer RM. Renal manifestations of Kawasaki’s disease. Pediatr Radiol. 1985;15(2):116–18.PubMedCrossRefGoogle Scholar
  12. 12.
    Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Pediatr Nephrol. 2007;22(7):987–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Bonany PJ, Bilkis MD, Gallo G, Lago N, Dennehy MV, Sosa del Valle JM, et al. Acute renal failure in typical Kawasaki disease. Pediatr Nephrol. 2002;17(5):329–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Mac Ardle BM, Chambers TL, Weller SD, Tribe CR. Acute renal failure in Kawasaki disease. J R Soc Med. 1983;76(7):615–16.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Sevin C, Heidet L, Gagnadoux MF, Cheron G, Niaudet P. [Acute renal insufficiency in Kawasaki disease]. Arch Fr Pediatr. 1993;50(6):505–7.PubMedGoogle Scholar
  16. 16.
    Veiga PA, Pieroni D, Baier W, Feld LG. Association of Kawasaki disease and interstitial nephritis. Pediatr Nephrol. 1992;6(5):421–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Krug P, Boyer O, Balzamo E, Sidi D, Lehnert A, Niaudet P. Nephrotic syndrome in Kawasaki disease: a report of three cases. Pediatr Nephrol. 2012;27(9):1547–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn Circ J. 1979;43(8):741–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Takahashi K, Oharaseki T, Yokouchi Y, Naoe S, Saji T. Kawasaki disease: basic and pathological findings. Clin Exp Nephrol. 2013;17(5):690–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Valentini RP, Smoyer WE. Renal vasculitis. In: Avner E, Harmon W, Niaudet P, editors. Pediatric nephrology. 5th ed. Philadelphia: Lippincott Williams Wilkins; 2004. p. 835–50.Google Scholar
  21. 21.
    Agard C, Mouthon L, Mahr A, Guillevin L. Microscopic polyangiitis and polyarteritis nodosa: how and when do they start? Arthritis Rheum. 2003;49(5):709–15.PubMedCrossRefGoogle Scholar
  22. 22.
    Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145(4):517–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Thibault S, Drolet R, Germain MC, D’Allaire S, Larochelle R, Magar R. Cutaneous and systemic necrotizing vasculitis in swine. Vet Pathol. 1998;35(2):108–16.PubMedCrossRefGoogle Scholar
  24. 24.
    Ozen S, Ben-Chetrit E, Bakkaloglu A, Gur H, Tinaztepe K, Calguneri M, et al. Polyarteritis nodosa in patients with Familial Mediterranean Fever (FMF): a concomitant disease or a feature of FMF? Semin Arthritis Rheum. 2001;30(4):281–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Bakkaloglu A, Ozen S, Baskin E, Besbas N, Gur-Guven A, Kasapcopur O, et al. The significance of antineutrophil cytoplasmic antibody in microscopic polyangiitis and classic polyarteritis nodosa. Arch Dis Child. 2001;85(5):427–30.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Brogan PA, Davies R, Gordon I, Dillon MJ. Renal angiography in children with polyarteritis nodosa. Pediatr Nephrol. 2002;17(4):277–83.PubMedCrossRefGoogle Scholar
  27. 27.
    Jelusic M, Vikic-Topic M, Batinic D, Milosevic D, Malenica B, Malcic I. Polyarteritis nodosa in Croatian children: a retrospective study over the last 20 years. Rheumatol Int. 2013;33(12):3087–90.PubMedCrossRefGoogle Scholar
  28. 28.
    Mondal R, Sarkar S, Pal P, Nandi M, Hazra A, Sabui TK. Childhood polyarteritis nodosa: a prospective multicentre study from eastern India. Indian J Pediatr. 2014;81(4):371–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Hall LD, Dalton SR, Fillman EP, Dohse L, Elston DM. Re-examination of features to distinguish polyarteritis nodosa from superficial thrombophlebitis. Am J Dermatopathol. 2013;35(4):463–71.PubMedCrossRefGoogle Scholar
  30. 30.
    Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus. 1998;7(4):238–58.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–20.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Bourgarit A, Le Toumelin P, Pagnoux C, Cohen P, Mahr A, Le Guern V, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine. 2005;84(5):323–30.PubMedCrossRefGoogle Scholar
  33. 33.
    Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44(3):666–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med. 1979;67(6):941–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol. 2006;2(12):661–70.PubMedCrossRefGoogle Scholar
  36. 36.
    Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367(3):214–23.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955–63.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999;42(3):421–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Hattori M, Kurayama H, Koitabashi Y, Japanese Society for Pediatric N. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J Am Soc Nephrol. 2001;12(7):1493–500.PubMedGoogle Scholar
  40. 40.
    Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, Kostic M, Markovic-Lipkovski J, Nikolic M, et al. Childhood microscopic polyangiitis associated with MPO-ANCA. Pediatr Nephrol. 2006;21(1):46–53.PubMedCrossRefGoogle Scholar
  41. 41.
    Handa R, Wali JP, Gupta SD, Dinda AK, Aggarwal P, Wig N, et al. Classical polyarteritis nodosa and microscopic polyangiitis – a clinicopathologic study. J Assoc Physicians India. 2001;49:314–19.PubMedGoogle Scholar
  42. 42.
    Yu F, Huang JP, Zou WZ, Zhao MH. The clinical features of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese children. Pediatr Nephrol. 2006;21(4):497–502.PubMedCrossRefGoogle Scholar
  43. 43.
    Ben Ameur S, Niaudet P, Baudouin V, Le Bourgeois M, Houdouin V, Delacourt C, et al. Lung manifestations in MPO-ANCA associated vasculitides in children. Pediatr Pulmonol. 2014;49(3):285–90.PubMedCrossRefGoogle Scholar
  44. 44.
    Jennette JC, Thomas DB, Falk RJ. Microscopic polyangiitis (microscopic polyarteritis). Semin Diagn Pathol. 2001;18(1):3–13.PubMedGoogle Scholar
  45. 45.
    Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.PubMedCrossRefGoogle Scholar
  46. 46.
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis. 1992;20(3):261–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Genereau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38(11):1638–45.PubMedCrossRefGoogle Scholar
  50. 50.
    Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40(4):757–63.PubMedCrossRefGoogle Scholar
  52. 52.
    Zauner I, Bach D, Braun N, Kramer BK, Funfstuck R, Helmchen U, et al. Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis. 2002;39(1):28–35.PubMedCrossRefGoogle Scholar
  53. 53.
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.PubMedCrossRefGoogle Scholar
  54. 54.
    Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803.PubMedCrossRefGoogle Scholar
  55. 55.
    Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Pendergraft 3rd WF, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol. 2014;9(4):736–44.PubMedCrossRefGoogle Scholar
  57. 57.
    Harper L, Savage CO. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol. 2000;190(3):349–59.PubMedCrossRefGoogle Scholar
  58. 58.
    De Lind van Wijngaarden RA, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol. 2008;3(1):237–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum. 2007;57(5):837–44.PubMedCrossRefGoogle Scholar
  60. 60.
    Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol. 2002;17(9):754–61.PubMedCrossRefGoogle Scholar
  61. 61.
    Frosch M, Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr. 2004;163(8):425–34.PubMedCrossRefGoogle Scholar
  62. 62.
    Siomou E, Tramma D, Bowen C, Milford DV. ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome. Pediatr Nephrol. 2012;27(10):1911–20.PubMedCrossRefGoogle Scholar
  63. 63.
    Stegmayr BG, Gothefors L, Malmer B, Muller Wiefel DE, Nilsson K, Sundelin B. Wegener granulomatosis in children and young adults. A case study of ten patients. Pediatr Nephrol. 2000;14(3):208–13.PubMedCrossRefGoogle Scholar
  64. 64.
    Khan I, Watts RA. Classification of ANCA-associated vasculitis. Curr Rheumatol Rep. 2013;15(12):383.PubMedCrossRefGoogle Scholar
  65. 65.
    Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71(6):955–60.PubMedCrossRefGoogle Scholar
  66. 66.
    Wegener’s Granulomatosis Etanercept Trial Research G. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352(4):351–61.CrossRefGoogle Scholar
  67. 67.
    Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335(1):16–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–100.PubMedCrossRefGoogle Scholar
  69. 69.
    Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine. 1999;78(1):26–37.PubMedCrossRefGoogle Scholar
  70. 70.
    Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;17(1):16–24.PubMedCrossRefGoogle Scholar
  71. 71.
    de Pablo P, Garcia-Torres R, Uribe N, Ramon G, Nava A, Silveira LH, et al. Kidney involvement in Takayasu arteritis. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S10–14.PubMedGoogle Scholar
  72. 72.
    Vaideeswar P, Deshpande JR. Pathology of Takayasu arteritis: a brief review. Ann Pediatr Cardiol. 2013;6(1):52–8.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–23.PubMedCrossRefGoogle Scholar
  74. 74.
    Ozen S, Duzova A, Bakkaloglu A, Bilginer Y, Cil BE, Demircin M, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150(1):72–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O, et al. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev. 2013;12(12):1143–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Evaluation of diagnostic (‘classification’) criteria in Behcet’s disease – towards internationally agreed criteria. The International Study Group for Behcet’s disease. Br J Rheumatol. 1992;31(5):299–308.Google Scholar
  77. 77.
    Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen S. Renal Behcet’s disease: a cumulative analysis. Semin Arthritis Rheum. 2002;31(5):317–37.PubMedCrossRefGoogle Scholar
  78. 78.
    Dolezalova P, Price-Kuehne FE, Ozen S, Benseler SM, Cabral DA, Anton J, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis. 2013;72(10):1628–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Pediatrics, Faculty of MedicineHacettepe UniversitySihhiyeTurkey
  2. 2.Department of Pediatric PathologyHacettepe UniversitySihhiyeTurkey

Personalised recommendations